SCHEDULE: Intracoastal Capital Reports 4.99% Stake in Enveric Biosciences

Intracoastal Capital, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 4.99% beneficial ownership stake in Enveric Biosciences, Inc. via a Schedule 13G filing.

Summary

• Reporting Persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital, LLC, collectively hold a beneficial ownership stake in Enveric Biosciences, Inc.
• The security class is Common Stock, par value $0.01 per share, with CUSIP number 29405E505.
• As of December 17, 2025, the Reporting Persons beneficially own 31,353 shares of Common Stock, representing approximately 4.99% of the class.
• This ownership is primarily derived from Intracoastal Warrant 1, which includes a blocker provision limiting exercise to prevent beneficial ownership from exceeding 4.99%.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 90,499 shares of Common Stock as of December 17, 2025.
• Immediately following a transaction on December 11, 2025, related to a Letter Agreement, the Reporting Persons were deemed to beneficially own 44,000 shares, representing approximately 7.4% of the 596,978 outstanding shares at that time, also subject to warrant blocker provisions.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a passive ownership stake. The presence of an institutional investor group is generally a positive signal, but the blocker provisions indicate a passive, non-influential role, which is neither strongly positive nor negative for the company's immediate operational outlook.

Positives

• A significant institutional investor group has taken a substantial, albeit passive, position in Enveric Biosciences, indicating potential confidence in the company's long-term prospects.
• The strategic use of blocker provisions in the warrants demonstrates a sophisticated approach to investment, allowing for a significant economic interest while avoiding the more stringent reporting and potential implications of exceeding the 5% beneficial ownership threshold.

Negatives

• The blocker provisions in the warrants limit the immediate exercisability of a larger stake, which could restrict the Reporting Persons' ability to fully capitalize on their investment quickly if the share price experiences rapid appreciation.

Risks

• The blocker provisions in the warrants prevent the Reporting Persons from exercising their full warrant holdings if doing so would result in beneficial ownership exceeding 4.99%, potentially limiting their upside participation.
• The existence of multiple warrants (Intracoastal Warrant 1, 2, and 3) implies potential future dilution for existing shareholders if these warrants are fully exercised, although the current blocker provisions mitigate this for the Reporting Persons' immediate stake.

Future Outlook

This filing is a historical disclosure of ownership and does not contain forward-looking statements or guidance from the company or the reporting persons regarding future performance or strategy, beyond the implicit intent to maintain a significant, albeit capped, stake.

Management Comments

• The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This Schedule 13G filing indicates an institutional investor group taking a passive stake in a publicly traded company, which is a common practice for investment funds. The use of blocker provisions is a standard mechanism for investors to manage their ownership percentage to avoid triggering more stringent reporting requirements (e.g., Schedule 13D) or other regulatory thresholds, particularly in smaller cap companies where a relatively small share count can quickly lead to significant percentage ownership.

Comparison to Industry Standards

• The 4.99% ownership stake is a common threshold for passive investors to report via Schedule 13G, specifically designed to avoid the more detailed and control-oriented Schedule 13D filing required for 5% or more ownership with intent to influence management.
• The inclusion of blocker provisions in warrants is a standard financial instrument design, frequently observed in financing rounds for biotech or early-stage companies, allowing investors to acquire a larger economic interest while remaining below specific beneficial ownership thresholds.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake. The blocker provisions ensure that this investor does not immediately seek to influence control, which might be reassuring for existing management and other shareholders.
• Company Management: Awareness of a significant passive investor holding warrants, which could be exercised up to the 4.99% threshold, but without an intent to influence control.

Next Steps

• The filing does not explicitly mention future actions or milestones for Enveric Biosciences or the Reporting Persons, beyond the ongoing passive ownership.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive ownership stake by an institutional investor group. It does not contain new operational or financial performance data for Enveric Biosciences that would warrant a change in investment recommendation. The investor group's decision to maintain ownership below the 5% threshold, utilizing blocker provisions, suggests a passive investment strategy rather than an intent to influence control, thus providing no strong catalyst for a 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and await further operational updates or financial results from the company.

Keywords

Enveric Biosciences, EVBC, Schedule 13G, Beneficial Ownership, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Common Stock, Warrants, SEC Filing, Institutional Investor, Blocker Provision